Now you’re working in San Francisco again. Was there an incentive for you to leave Japan? Was it simply the opportunity to work in the lab in San Francisco?

Shinya Yamanaka: Well, that’s what I heard. Some people moved to the UK and some people moved to Singapore because of the difficulties of working on ES cells. But now we have iPS cells, I think that problem has been overcome. Hopefully many scientists will come back to the States.

Because of his success, we have new opportunities to prepare cardiac cells and neural cells to transplant into patients. So when I saw his paper, I thought, “Wow! It’s just amazing.” But after that, I realized some problems with human ES cells.

In science, because it’s based on experimentation, it seems that scientists rely on failure, not only to tell them what not to do, but what to do first.

(At the 2008 International Achievement Summit in Kailua-Kona, Hawaii, Dr. Yamanaka participated in a panel discussion of genetics in medicine. An excerpt from his remarks on that occasion precedes the text of this interview.)

Shinya Yamanaka: Even when I was a high school student I wanted to be a physician. That was because, as I mentioned, I played judo. And I got injured so many times — I fractured myself more than ten times — so I saw an orthopedic surgeon so many times. It was very natural for me to become a doctor.

Dr. Yamanaka now divides his time between professorships at Kyoto University and the University of California’s Gladstone Institutes in San Francisco. A vigorous and athletic man, he continues to work long days, relishes his scientific pursuits and peppers his conversation with jokes in a way that his colleagues find more American than Japanese. Still an enthusiastic athlete, he enjoys a brisk run or swim between marathon sessions in the laboratory.

Shinya Yamanaka: ES cells have two important properties.  The first one: we can proliferate — we can culture ES cells as much as we want.  So from a single ES cell we can have a million, billion or more ES cells within a certain period of time.  The other important property of ES cells is something called pluripotency.  So pluripotency means that we can make any types of cells that exist in our body.  We have more than 200 types of cells in our body.  So we can make those 200 types of cells from ES cells.  So that’s the second important property of ES cells.

Liquidcrystallens

The news of Dr. Yamanaka’s discovery, quickly confirmed by other laboratories working independently, spread like wildfire through the scientific world. Everywhere, the same question sprang to mind. Would Yamanaka’s technique work with human cells as well as those of mice? An additional concern arose. Of the four gene combinations Yamanaka had used, two have been implicated in cancer. One of these has a relatively weak statistical relationship with cancer, but the other, c-Myc, is a well-known cancer gene.

Shinya Yamanaka: Failure is very important. Failure is kind of a beginning of success. Even in my own scientific experiments, I had many, many failures. But in many cases, those negative results gave me many insights into new directions, as you go. You know, in Japan we have a short sentence which — in Japanese it’s stem batoh. That means if you fell down seven times, you have to wake up [get up] eight times, then you can succeed. So I think that’s very true in science.

Shinya Yamanaka: For the last ten years or so I have been working on stem cells, especially embryonic stem cells, ES cells. When I started working on ES cells, most people were trying to generate some kind of cells such as cardiac cells or neurocells from ES cells. So that kind of project was not so risky, because many people are trying to do that. To me, at that time, the most risky project was the reverse. Instead of making some special cells from ES cells, I wanted to make ES cells from, like, skin cells. So it’s the opposite direction, and I knew it would be very risky. The chance is very small.

Shinya Yamanaka: I did my post-doc training in San Francisco, and I’m very grateful to the city of San Francisco and the institute where I did my post-doc training. So it was kind of a dream to come back to San Francisco, to that institute. That’s the main reason.

Shinya Yamanaka: The Gladstone Institute has a strong, strong research project in the three major diseases in the States and in the world. That is, cardiovascular disease, neural disease and HIV. I believe that our technology, iPS cell technology, can be used in all three of those areas of human disease. I already have a strong collaboration with many, many scientists at Gladstone.

Shinya Yamanaka: In my Ph.D. school, I didn’t work on stem cells.  I just worked on basic pharmacology.  But by doing pharmacology, I got very interested in so-called “knockout mouse” technology.  Knockout mouse is a way to study the function of genes. You know, both human and mouse have approximately 20,000 genes. With knockout mouse technology, we can select one gene out of those 20,000 genes, and completely destroy that one particular gene so that we can understand the function of that particular gene. I got very interested in that technology.  It was 1992 or 1993 when I graduated from my Ph.D. school. So I decided to study — I decided to learn about knockout mouse technology.  But at that time in Japan, only a few scientists were working on knockout mouse technology.  That’s why I decided to move to the States, San Francisco.

Shinya Yamanaka: I liked school pretty much. I liked to study, and I also liked to play some sports. I played judo. It’s a traditional Japanese sport. So yeah, I liked my school pretty much.

Fill in your E-mail and we will send you a one time password, you can use to login with. Once logged in, you can change your password if you wish. Please note: The temporary code will only be active for 15 min.

Besides your parents, were there others who supported you when you were growing up? In the university, or perhaps a judo coach?

Shinya Yamanaka: In the next five years, I think scientists will make iPS cells from many patients so that they can study the cause of diseases more extensively, and so that they can search for more effective drugs. I think that will happen in the next three, four, five years.

Shinya Yamanaka: In order to achieve something, it’s very important that it should be very risky, because if it’s not risky, that means it’s very easy, many people can achieve that. But if you really want to solve very tough questions, or very difficult goals, you really have to take risks.

Shinya Yamanaka: Yes, actually. One of the three genes, Klf4, had some relationship with cancer, but compared to c-Myc, the risk is much, much smaller.

Optotune

Dr. Yamanaka, you’ve been exploring a new form of stem cell research. How did you become involved in this work, and what do you see as the promise of stem cell research?

Frustrated with his lack of support at Osaka, Yamanaka considered returning to medical practice, when the opportunity arose to lead his own laboratory at another university in nearby Nara. He knew that if his new laboratory were to thrive, he would need to attract first-rate graduate students and postdoctoral fellows with a unique and intriguing research project. One day, while visiting a friend’s fertility clinic, Dr. Yamanaka found himself gazing at human embryos through a microscope and became convinced that an alternative to the use of embryonic tissue in stem cell research must be found. While most contemporary stem cell research involved controlling the process by which the stem cells differentiated into other cell types, Yamanaka decided he would pursue the opposite course, reprogramming the cells of an adult animal to return to their embryonic pluripotent state.

In this country, a lot of funding for scientific research is controlled by the federal government. Have you seen any negative results or obstruction because of the current administration’s views on funding for this field of science?

To incorporate objects or to fill cavities by combining materials of different nature. a two-pack, transparent, epoxy product, for indoor use. It features high transparency, no shrinkage, and low yellowing.

The idea seemed improbable to most of his peers, and the chances of success marginal, but the idea was so unusual, his lab attracted exceptionally talented students. Identifying the combination of genes that would convert adult cells back into their pluripotent state could require testing hundreds of possible combinations, the work of decades. Working 12 to 16 hours a day for months on end, Yamanaka reviewed the existing literature, and tried to identify the most promising combinations. Balancing meticulous research with informed intuition, he compiled a list of the 24 most likely combinations, and decided to test those first. In 2006, only five years into his project, he found a combination of four genes that converted the skin cells of an adult mouse back to their pluripotent state. His hunch had paid off, saving his team years of work.

Shinya Yamanaka: The biggest problem is a safety issue. ES cells are derived from embryos, and embryos are pluripotent from the beginning. By contrast, iPS cells are derived from skin cells or other types of somatic cells and those cells are not really potent anymore. We have to put three or four genes into skin cells in order to convert or in order to induce pluripotency. It’s kind of a de-differentiation, and de-differentiation is a common feature between deprogramming and cancer. So what I’m really afraid of is that the technology we’re doing now is not only making iPS cells, but also making tumor cells. So we really have to double-check the safety, safeness of iPS cells we generated by our method. Because in the future, we want to use these iPS cells in regenerative medicine, that means we would like to transplant iPS cells — derived cardiac cells or neural cells — into patients. So that kind of safety issue is crucial.

Shinya Yamanaka: By collaborating with him, we can make iPS cells from various patients who are not so common in Japan or in San Francisco. So we can enlarge our project by collaborating with many scientists including Dr. Ian Wilmut.

Shinya Yamanaka: I was born in Osaka, Japan. It was 45 years ago. My father has a small factory in Osaka, and we lived next to his factory, so I was surrounded by many types of machines. Even as a child, my hobby was using those machines. I was a kind of technical person from the very beginning.

Shinya Yamanaka: I did talk to him about that, but I forgot the real reason. Maybe he didn’t tell me the real reason, but I can imagine it would be very difficult for a scientist like him, who studied for a new project, to say that, “I’m going to stop this.” So I think he’s, in a sense, very brave, and I admire him so much. And that’s a good lesson for me too. Since this technology is still very young, iPS cell technology is very young, I may have to do the same thing in the future. If some other method comes up, and which, if it’s much better then iPS cell technology, I think I should be brave enough to say that we should not continue iPS cell technology. Instead we should do this new technology. I hope I will be brave enough like Dr. Wilmut.

Shinya Yamanaka: iPS cells and ES cells are indistinguishable in many aspects. We have good conditions for mouse and human ES cells to maintain pluripotency. We can use exactly the same conditions to maintain mouse and human iPS cells. So it is not so difficult. Pluripotency is the most important property of ES and iPS cells, because with the pluripotency, we can make many types of cells from stem cells.

Yamanaka was thrilled with the research opportunities he enjoyed in the United States. When he was offered an assistant professorship at Osaka, he returned to Japan with a cage full of genetically engineered mice for experimentation. Unfortunately, he lacked the staff to do much more than look after his research animals, without pursuing any new projects. By this time, Yamanaka had married and started a family, but his professional life was stalled. His situation at Osaka was especially disappointing because he was eager to apply knockout mouse technology to the newly emerging field of stem cell research. Stem cells are the undifferentiated cells found in the embryos of all animals. As the embryonic creature gestates, these cells differentiate, becoming the cells that make up bone, blood, nerves and other tissues. At the close of the 20th century, stem cell research in both Japan and the United States was encumbered with a major ethical controversy. The best sources of human stem cells were the embryos discarded by fertility clinics, but destroying human embryos for research purposes struck government leaders in both countries as morally unacceptable. In 2001, U.S. President George W. Bush explicitly barred federal funding for any research involving the creation of new stem cell lines from human embryos. In Japan, the rules regarding research with embryonic tissue were even more stringent. Yamanaka considered the possibility that the cells of an adult animal could be reprogrammed to their embryonic, pluripotent state.

For a decade, the debate over human stem cell research had pitted the ethical concerns of religious leaders and policymakers against the demands of medical research. Human stem cell research has long offered the promise of curing and preventing otherwise untreatable diseases and injuries, but the only pluripotent stem cells available for experimentation were those harvested from fetal tissue or from discarded human embryos. Moral objections to this research led a number of governments — including those of Japan and the United States — to impose stringent restrictions on further research.

Shinya Yamanaka: No. Actually, I did not graduate from Osaka University. I graduated from Kobe University. It’s like two hours by car from Osaka to Kobe.

What were some of the challenges in working with the mice? Is it true that the mice had to be interbred, and then the cells had to be infected with a virus carrying the gene?

Shinya Yamanaka: Treating cancers is still very difficult, but I hope that within the next 15 or 25 years, most of the cancers will be cured. Right now it’s still very difficult.

Repeating the process with human cells posed additional difficulties, including the possibility of an increased risk for cancer, but Yamanaka had become adept at overcoming difficulties and accomplishing his research goals at record speed. Within a year, Yamanaka had duplicated the results with human cells. In the process, he learned that c-Myc could be omitted from the combination, generating the same results with a greatly decreased risk of cancer. His accomplishment was recognized with honors from governments around the world, including the Osaka Science Prize in Japan, and the Lasker Award in the United States. In 2012 he received the Nobel Prize in Medicine.

Shinya Yamanaka: Because of this technology, iPS technology, now we can prepare many types of human cells. For example, heart cells — cardiac cells — or neural cells from patients. So you can easily imagine that without this technology, it’s impossible to take cardiac cells from patients who have some kinds of cardiac diseases. If the patient dies, we may be able to get a small amount of cardiac cells from that patient, but those cells do not proliferate, so we cannot increase the number. But with this technology, all we need is a small piece of skin from that patient, and by making iPS cells, we can increase the number of cells as much as we want. And then we can make cardiac cells from those iPS cells. So I think for the first time in the history of medicine, we now have an opportunity to prepare many, many cardiac or neural cells directly from patients, and those cells should be very, very useful, to understand why those patients become sick. And to search for very effective drugs for that patient, and also to study — to predict — any side effect for that particular patient. So that is the most beautiful approach — I mean application — of this iPS cell technology.

Shinya Yamanaka: Of course we are getting a lot of e-mails and phone calls, first of all from patients, and from many press people. We can spend very limited time on science and it isn’t good. We really have to go back to science because this technology is not mature enough. There are many things we still have to overcome before we can apply this technology to clinics.

Shinya Yamanaka: Well, we have mouse ES cells and human ES cells. They are common, in that they are pluripotent. But they are different, so different in many aspects. They look different. The morphology of mouse ES cells and human ES cells are totally different, and the culture condition of mouse and human ES cells are also different. So from those substantial differences, I thought that the same three or four factors may not work on human cells. But it turned out the same factors can generate human iPS cells, so it was rather surprising to us.

Shinya Yamanaka: Yes. In Osaka I almost worked by myself. I used many, many mice. I had almost 1,000 mice for my own project, and I had to take care of all of them by myself. So it was a lot of work. After I moved to Nara, I had many, many technicians and students who helped me. So I was not alone, that’s very important for me.

In San Francisco you’re working at the University of California and the Gladstone Institute of Cardiac Disease. What are your goals in attaching yourself to these institutions?

Shinya Yamanaka: When I was a junior high school student, I was very interested in science. At that time, I wanted to become a scientist as well. After I went to senior high school, being a doctor was my dream, so I didn’t imagine I would be a scientist.

Dr. Yamanaka, many of the scientists we’ve spoken with say that failure is the biggest teacher. Have you experienced that in your career?

Liquid lensedmund optics

Shinya Yamanaka: No, I don’t think so. Many fathers want at least one of their boys to take over his own company. It’s very typical in Japan. But he knew how difficult it is to run a small company. He thought I would not be good at running a company, so instead he encouraged me to be a doctor.

Shinya Yamanaka: Funding is essential. Without funding you cannot continue a long project. Since this project was risky, everybody can tell that it won’t work, so I had a hard time to get enough funding. But back in Japan, I was very lucky to have a five-year period of relatively big funding by the Japanese government. But that program was — how to say? One very famous Japanese scientist was handling that funding program. I presented our data and our project to him and he told me that, “I knew this wouldn’t work.” But he said he thought this was a good challenge to be funded. So I was very lucky to get some good funding. So I think I really need that kind of person who can predict which risky project would be funded. It’s a very difficult job, but I think that kind of person would be essential.

Tubelens

Let’s take a moment to really define what your stem cell breakthrough is, and we’ll go from there to the impact it has on the future of medicine. Instead of using embryonic stem cells, you have taken skin cells, and what have you done with them?

Shinya Yamanaka: Yes, because I had a medical license. Although I’m not so good at seeing patients, because I only did two-year residency in orthopedic surgeon. I think having a medical license is kind of a backup. I can always go back to clinics and do a training again. That did help me to do some very risky projects in science.

Shinya Yamanaka: That’s a good point. Originally we thought four genes are required and one of the four genes is very dangerous because it’s c-Myc. It’s a famous cancer-causing gene. By modifying our protocol, we were able to omit the usage of c-Myc. So now we only need three genes, not four genes.

Shinya Yamanaka: There are many diseases which we cannot cure with the current medical technologies, and it is basic science which can cure those diseases and those patients. So I hope many, many talented, young students will be scientists.

Shinya Yamanaka: I really had hard times, so I was about to quit doing science. I was about to go back to clinics, but again, I was lucky to find another position, in Nara. Nara is very close to Osaka. It’s only one hour by car. There’s another university in Nara, and I was lucky enough to find a position as an associate professor over there. The funding was much better, and the scientific atmosphere was much better over there. That means there are many, many good scientists in that university in Nara. So without that promotion, probably I [would have] quit my scientific career.

Shinya Yamanaka: After finishing my post-doc training in San Francisco, I went back to Osaka in 1996, and I was lucky to get an assistant professor position in the same laboratory where I got my Ph.D. But compared to my scientific career in the States, in San Francisco, I had a hard time after going back to Japan, because the funding was not good enough back in Osaka. And at that time I only had a few scientists around me who I can discuss with. So I had a hard time in the first two or three years after I went back to Japan, Osaka.

Shinya Yamanaka: It must be infected by viruses having those four factors — three or four factors. So viruses function as a so-called vector to deliver genes into cells. It’s just like a gene therapy. In gene therapy, you use retrovirus to transfer one gene into patients. So we use the same retroviral system in order to transfer — deliver — three genes into skin cells. As you may recall, gene therapy to immune-deficient children was very effective in the beginning. But unfortunately, more than 50 percent of those patients who got gene therapy developed tumors — leukemia — after the treatment. That was because of the retroviral integration into a host genome. So we have to worry about the same type of tumor, leukemia, in iPS cell technology.

Shinya Yamanaka was born in Osaka, Japan, where his father owned a small factory. Surrounded by machinery, young Shinya developed an enthusiasm for all technical subjects. In school, he was drawn to science; he was also an enthusiastic athlete. His passion for judo resulted in a number of broken bones and frequent visits to the orthopedist. Although he ultimately earned a black belt in judo, these experiences also awakened his interest in medicine. After graduating from a high school attached to the university in Osaka, he earned a medical degree at Kobe University. He completed a residency in orthopedic surgery at National Osaka Hospital, but became frustrated with his lack of dexterity as a surgeon. He decided to pursue a career in research instead, and enrolled at Osaka University, earning a Ph.D. in pharmacology. In graduate school, a chance reading of a paper on genetically engineered mice, so-called “knockout mice,” led him to the study of gene replacement. By eliminating individual genes from the mouse genome, scientists were able to learn the function of each gene. Yamanaka was eager to work with this new technology, but there were no institutions pursuing this research in Japan. He wrote to 30 universities and laboratories in the United States, searching for a postdoctoral fellowship in the field, before finding a place at the University of California, San Francisco.

Shinya Yamanaka: Because of my family, it’s very difficult to completely move from Japan to San Francisco, so now I have two laboratories, one in Japan and one in San Francisco. The one in Japan, in Kyoto, is much, much bigger, so right now I can only stay in San Francisco a few days every month. I have to commute every month.

Shinya Yamanaka: Actually it worked, yes. I got more then 20 or 30 applicants that year. I could only afford three students, so I was able to select the three best students out of those 30 applicants, and they did very well.

Dr. Yamanaka, we’d like to ask a few questions about your childhood. Where were you born and what was your childhood like?

Shinya Yamanaka: I remember I read many books about physicians. Not a novel, but a real story. I was very interested in how physicians were trying to help patients.

Tunablelens

Shinya Yamanaka: Yes. Dr. Wilmut showed that somatic cells, like skin cells, can be reprogrammed. That was the beginning of my project. From his achievement, I learned that eggs — human or mouse eggs — can be programmed from skin cells. From his success I thought that there must be some factors within the egg that can reprogram somatic skin cells, and I decided to search for such reprogramming factors.

When you began your work with human cells, how likely did it seem to you that the same three or four genes that reprogrammed skin cells in mice could do the same thing in humans?

Shinya Yamanaka: I was an orthopedic surgeon, and my first failure was that I was not good at doing surgery, and that failure gave me an opportunity to move to basic science.  Then my first major was pharmacology, and in pharmacology we only use many inhibitors and stimulators, all just drugs. And any drug cannot be 100 percent specific and 100 percent effective.  So although I did many, many experiments, I did not obtain the answer, because  the drugs I used weren’t specific enough. So that was kind of my second failure in my career.  But that second failure got me interested in knockout mice, mouse technology. So I think failure is important in my career.

Shinya Yamanaka: I didn’t expect such a rapid decision, because he kind of gave up doing cloning anymore. But I think this technology is still very young. There are many problems which we have to overcome. So I think we still have to study nuclear cloning, nuclear transfer. So I was very surprised to hear that he decided to stop doing any cloning experiments.

When Dr. Shinya Yamanaka of the University of Kyoto succeeded in converting the skin cells of adult mice back into a stem cell-like pluripotent state, the news spread like wildfire through the scientific world. Everywhere, the same question sprang to mind. Would Yamanaka’s technique work with humans as well as mice? By the end of the year, Yamanaka had duplicated the results with human cells. His discovery was hailed by scientists and religious leaders as a breakthrough that overcame the moral objection to stem cell research.

The dominant trend in research at the time was trying to make different kinds of cells from stem cells. It’s surprising to hear that there was so much interest in your work, when you were trying to do the reverse, make stem cells from ordinary cells. Did it surprise you that you would have that kind of response?

Shinya Yamanaka: It’s very simple. All we have to do is to put three genes — namely Oct-3/4, SOX2 and Klf4 — into adult skin cells, and those three genes can convert skin cells into stem cells.

Shinya Yamanaka: The real risk was to start this project in mice, because we knew that chance is very, very small, and we thought it might take 20 — or maybe 30 — years. So moving from mouse to human was not so big a step. The first step was the highest step for us.

Deep optics

Shinya Yamanaka: Yes. If I had to use eggs, it would have been more difficult, but another scientist in Japan Dr. Takastada ? (ph.) saw that not only eggs, but also ES cells themselves can be programmed skin cells. So from his success, I learned that I didn’t have to use eggs. Instead I can use ES cells, and ES cells are much easier to handle.

Shinya Yamanaka: It may be surprising, but I was a surgeon, like 20 years ago.  And I found I was terrible in the operating room.  So I thought, “Well, I won’t help people by doing this!” That’s why I decided to move to basic science, and I hope it’s working. So, for the last — let me see — for the last 12 years I have been working on embryonic stem cells, ES cells.  And I think probably… so please raise your hand if you know about ES cells.  Oh, not all. Okay.  Embryonic stem cells are stem cells which scientists generated from fertilized eggs. It was first derived from the mouse embryo in 1981, so 27 years ago.  ES cells have two properties, very important properties.  The first one: you can increase — you can culture — ES cells as much as you want, almost forever.  The second, very important point of ES cells is that you can induce, you can make any types of cells from ES cells, including cardiac cells, neural cells, blood cells, and also germ cells. That means you can prepare any cells, in any quantity, any time.  Because of that, mouse embryonic stem cells — ES cells — gave rise to a new technology called “knockout mouse” technology, which is a super technology in understanding the gene function. And as you may know, knockout mouse technology was awarded the Nobel Prize last year.  Then in 1998, Dr. James Thomson developed ES cells from human blastocysts. That opened up a completely new way in regenerative medicine.

Wasn’t it significant that Dr. Wilmut decided not to renew the permission he’d been granted for working with embryonic stem cells?

Shinya Yamanaka: Usually to find a job in the States — from Japan — usually you have to ask your professor in Japan to recommend some place. But unfortunately, at that time, my professor — my mentor in Japan — did not know any labs working on knockout mice. So I did not get any good recommendations. So I had to apply for many positions, which I learned from scientific journals such as Nature and Science. I applied to — I forget — like 20 or 30 different universities and laboratories in the States. And UCSF — University of California at San Francisco — was the first to give me an opportunity. That was why I ended up coming to San Francisco.

Shinya Yamanaka: As a scientist who developed this iPS technology, I hope to see that technology used in clinics. That’s my hope. At the same time, if this technology is not good, I’d like to say no to this technology myself. Right now I have to be very neutral. Again, this technology is still very young. We have very good hopes, but there are many, many hurdles as well. So I really have to say yes or no to this technology myself, that’s my hope.

We’d like to ask you about Ian Wilmut, who’s also an Academy member, best known for his achievement cloning a sheep, Dolly, from a single adult sheep cell. Because of your breakthrough, he’s changing the direction of his work. Would you like to comment on this?

In 2007, the world of science was stunned to learn that a lone researcher, working in a small, underfunded laboratory in Kyoto, Japan had made a historic breakthrough.

Shinya Yamanaka: Yes, they were very supportive. My father had a small company, and I was the only boy in the family. It’s kind of surprising he didn’t want me to take over his job. Instead, he encouraged me to be a doctor.

Shinya Yamanaka: When I went to my second lab, in Nara, it was my first time to be the so-called “principal investigator.” So I became independent for the first time in my scientific career. That means I will have to have many students and many post-docs, so I thought I really have to have some wonderful research project in my own lab to attract as many people as possible. So I thought what the goal should be, and I thought making stem cells from patients’ own cells should be my goal. That was the beginning of my full research.

You have to use human embryos to prepare human ES cells.  And some people do not like that idea, including the president of your country.  And also, because ES cells are not the patients’ own cells, we have to deal with immune rejections after transplantation.  So we decided to start a new project of our laboratory, in which we tried to generate ES-like stem cells, not from embryos, but from patients’ own cells. We thought the project would be very, very risky, challenging, and it would take 20 or 30 years.  But it turned out it took only five years to achieve that goal in a mouse.  So we were able to publish the generation of new stem cells — which were designated “iPS cells,” induced pluripotent stem cells  — from mouse skin cells in 2006. And last year we were able to translate that technology to the human.  So we and James Thomson, almost at the same time, were able to report that we can make ES-like stem cells without using embryos.  We can convert a patient’s skin cells directly to ES-like stem cells.

Shinya Yamanaka: Yes. My father and my mother encouraged me to do whatever I wanted to do. That was very good for me. You know, I was a doctor before I moved to basic science. I didn’t have any physicians in my family, but since my father told me I can do whatever I want, that was why I decided to… I decided to be a doctor.